[go: up one dir, main page]

PH12013501268A1 - Continuous arycyclic compound - Google Patents

Continuous arycyclic compound

Info

Publication number
PH12013501268A1
PH12013501268A1 PH1/2013/501268A PH12013501268A PH12013501268A1 PH 12013501268 A1 PH12013501268 A1 PH 12013501268A1 PH 12013501268 A PH12013501268 A PH 12013501268A PH 12013501268 A1 PH12013501268 A1 PH 12013501268A1
Authority
PH
Philippines
Prior art keywords
arycyclic compound
continuous arycyclic
compound
continuous
obesity
Prior art date
Application number
PH1/2013/501268A
Inventor
Takashi Goi
Norimitsu Hayashi
Ritsuo Imashiro
Kenji Morokuma
Osamu Sakurai
Kunio Saruta
Hiroaki Sawamoto
Hiroaki Shitama
Hidekazu Tsujishima
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of PH12013501268A1 publication Critical patent/PH12013501268A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.
PH1/2013/501268A 2010-12-17 2011-12-16 Continuous arycyclic compound PH12013501268A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424365P 2010-12-17 2010-12-17
PCT/JP2011/079958 WO2012081736A1 (en) 2010-12-17 2011-12-16 Continuous arycyclic compound

Publications (1)

Publication Number Publication Date
PH12013501268A1 true PH12013501268A1 (en) 2016-04-01

Family

ID=46244825

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/501268A PH12013501268A1 (en) 2010-12-17 2011-12-16 Continuous arycyclic compound

Country Status (18)

Country Link
US (2) US9302996B2 (en)
EP (1) EP2651915B1 (en)
JP (1) JP5629380B2 (en)
KR (1) KR101530141B1 (en)
CN (1) CN103261185B (en)
AU (1) AU2011342039B2 (en)
BR (1) BR112013014966B1 (en)
CA (1) CA2821900C (en)
DK (1) DK2651915T3 (en)
ES (1) ES2586385T3 (en)
HU (1) HUE029002T2 (en)
MX (1) MX347054B (en)
PH (1) PH12013501268A1 (en)
PL (1) PL2651915T3 (en)
PT (1) PT2651915T (en)
RU (1) RU2538964C1 (en)
TW (1) TWI537257B (en)
WO (1) WO2012081736A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013187496A1 (en) 2012-06-15 2013-12-19 田辺三菱製薬株式会社 Aromatic heterocyclic compound
JP5721032B2 (en) * 2012-06-15 2015-05-20 田辺三菱製薬株式会社 Pharmaceutical composition
PL3013796T3 (en) * 2013-06-27 2020-06-15 Lg Chem, Ltd. Biaryl derivatives as gpr120 agonists
ES2886641T3 (en) 2014-08-11 2021-12-20 Angion Biomedica Corp Cytochrome P450 inhibitors and their uses
CA2961628A1 (en) * 2014-09-17 2016-03-24 Prevacus, Inc. Synthesis of ent-progesterone and intermediates thereof
PH12017501029B1 (en) * 2014-12-24 2022-04-27 Lg Chemical Ltd Biaryl derivative as gpr120 agonist
US10287282B2 (en) 2014-12-31 2019-05-14 Angion Biomedica Corp. Methods and agents for treating disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0533268T3 (en) 1991-09-18 2001-12-03 Glaxo Group Ltd Benzanilide derivatives as 5HT-1D antagonists
HU219598B (en) 1992-12-17 2001-05-28 Sankyo Co. Ltd. Imidazole and pyridine derivatives of biphenyl compounds, a process for their preparation and pharmaceutical compositions containing these compounds
FI935373A0 (en) 1993-12-01 1993-12-01 Iws International Inc Kopplingsstycke eller koppling Foer ledning
WO1999058518A2 (en) 1998-05-12 1999-11-18 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
AU2935200A (en) 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
GB2351081A (en) * 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
CA2452391A1 (en) 2001-07-09 2003-01-23 Axys Pharmaceuticals, Inc. 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
BRPI0212775B8 (en) 2002-01-28 2021-05-25 Fuji Yakuhin Co Ltd composed of 1,2,4-triazole and drug
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
US7358364B2 (en) 2003-04-30 2008-04-15 The Institute For Pharmaceutical Discovery Llc Substituted carboxylic acids
AR044152A1 (en) * 2003-05-09 2005-08-24 Bayer Corp RENTAL DERIVATIVES, METHOD OF PREPARATION AND USE FOR THE TREATMENT OF OBESITY
MX2007003325A (en) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors.
JP2009505962A (en) * 2005-07-29 2009-02-12 バイエル・ヘルスケア・エルエルシー Production and use of biphenyl amino acid derivatives for the treatment of obesity
RU2474576C2 (en) 2006-11-29 2013-02-10 Эбботт Лэборетриз Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
JP2008255024A (en) 2007-04-02 2008-10-23 Banyu Pharmaceut Co Ltd Biarylamine derivatives
WO2009011285A1 (en) 2007-07-13 2009-01-22 Taisho Pharmaceutical Co., Ltd. Heteroarylbenzene compounds
WO2009079593A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor
WO2009126861A2 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolopyridine compounds useful as dgat1 inhibitors
AU2010226829A1 (en) 2009-03-18 2011-09-15 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
WO2011002067A1 (en) 2009-07-02 2011-01-06 武田薬品工業株式会社 Heterocyclic compound and use thereof
AU2011279509A1 (en) 2010-07-13 2013-01-10 Merck Sharp & Dohme Corp. Spirocyclic compounds
AU2011282989A1 (en) 2010-07-28 2013-01-10 Merck Sharp & Dohme Corp. Imidazole derivatives
WO2012044567A2 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Imidazole derivatives
WO2012047772A2 (en) 2010-10-07 2012-04-12 Schering Corporation Imidazole derivatives

Also Published As

Publication number Publication date
ES2586385T3 (en) 2016-10-14
BR112013014966B1 (en) 2020-02-18
PT2651915T (en) 2016-07-14
PL2651915T3 (en) 2016-11-30
US9975871B2 (en) 2018-05-22
EP2651915B1 (en) 2016-05-25
AU2011342039B2 (en) 2015-06-11
US20130261128A1 (en) 2013-10-03
CA2821900C (en) 2015-12-08
KR20130106422A (en) 2013-09-27
EP2651915A1 (en) 2013-10-23
BR112013014966A2 (en) 2016-09-13
MX347054B (en) 2017-04-07
EP2651915A4 (en) 2014-05-28
JP5629380B2 (en) 2014-11-19
RU2013132961A (en) 2015-01-27
HK1188597A1 (en) 2014-05-09
TWI537257B (en) 2016-06-11
US9302996B2 (en) 2016-04-05
US20160272614A1 (en) 2016-09-22
DK2651915T3 (en) 2016-07-18
MX2013006874A (en) 2013-07-05
CN103261185B (en) 2014-12-10
KR101530141B1 (en) 2015-06-18
CN103261185A (en) 2013-08-21
JP2013545719A (en) 2013-12-26
CA2821900A1 (en) 2012-06-21
TW201305126A (en) 2013-02-01
RU2538964C1 (en) 2015-01-10
WO2012081736A1 (en) 2012-06-21
HUE029002T2 (en) 2017-01-30

Similar Documents

Publication Publication Date Title
TN2011000400A1 (en) Inhibitors of beta-secretase
PH12013501268A1 (en) Continuous arycyclic compound
PH12014502733A1 (en) Neprilysin inhibitors
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
IN2014CN03159A (en)
MY170935A (en) Neprilysin inhibitors
CA2875877C (en) Syk inhibitors
MY172924A (en) Neprilysin inhibitors
SG191175A1 (en) Neprilysin inhibitors
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
PH12013502112A1 (en) Amide compound and pharmaceutical application therefor
PH12014500987A1 (en) Neprilysin inhibitors
AU2012214029A8 (en) Rorgammat inhibitors
MY163394A (en) Substituted aminobutyric derivates as neprilysin inhibitors
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
WO2008109991A8 (en) Inhibitors of carnitine palmitoyltransferase and treating cancer
MX2010008460A (en) Thiazole derivative and use thereof as vap-1 inhibitor.
UA105527C2 (en) Matriptase inhibitor compound for the treatment of cancer
PH12013502542B1 (en) Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant
IN2012DN02502A (en)
WO2011123536A8 (en) Polycyclic tetracycline compounds
WO2009015485A8 (en) Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
WO2010132670A3 (en) Pentacycline compounds
NZ605804A (en) New aminopyrazoloquinazolines
GB201020397D0 (en) Compounds